Tranilast: a novel weapon against insulin resistance.
Oxidative stress and inflammatory cytokines such as monocyte chemoattractant protein 1 (MCP-1), TGF-beta, and IL-2 are supposed to play crucial roles in the pathogenesis of insulin resistance (IR). Tranilast is an anti-allergic drug which exerts anti-inflammatory and anti-angiogenesis effects through inhibition of expression of MCP-1, TGF-beta, and antigen-induced IL-2 lymphocyte responsiveness. It also possesses a certain antioxidant activity. Considering the above facts and in view of its safety, tranilast may prove invaluable in the treatment of IR.
Namazi
M R
MR
Dermatology Department, Shiraz University of Medical Sciences, P.O. Box 71955-687, Shiraz, Iran. namazi_mr@yahoo.com
Soma
J
J
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D018932:Chemokine CCL2 / Q000096:biosynthesis / Q000235:genetics; D016207:Cytokines / Q000502:physiology; D003864:Depression, Chemical; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000235:genetics; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008954:Models, Biological; D018384:Oxidative Stress; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics; D062367:ortho-Aminobenzoates / Q000494:pharmacology / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D016207:Cytokines; D007376:Interleukin-2; D016212:Transforming Growth Factor beta; D062367:ortho-Aminobenzoates; D018799:Intercellular Adhesion Molecule-1; C012293:tranilast